Loading…
Pharmacological aspects and spectrum of action of ceftazidime–avibactam: a systematic review
Purpose Ceftazidime–avibactam is an antimicrobial association active against several Enterobacteriaceae species, including those resistant to carbapenem. Considering the importance of this drug in the current panorama of multidrug-resistant bacteria, we performed a systematic review about ceftazidim...
Saved in:
| Published in: | Infection 2018-04, Vol.46 (2), p.165-181 |
|---|---|
| Main Authors: | , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c438t-f4965f8b93ef07ca6f333cf69337ac184b4a5d52063920d2878b114d423af45e3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c438t-f4965f8b93ef07ca6f333cf69337ac184b4a5d52063920d2878b114d423af45e3 |
| container_end_page | 181 |
| container_issue | 2 |
| container_start_page | 165 |
| container_title | Infection |
| container_volume | 46 |
| creator | Tuon, Felipe Francisco Rocha, Jaime L. Formigoni-Pinto, Marcelo R. |
| description | Purpose
Ceftazidime–avibactam is an antimicrobial association active against several
Enterobacteriaceae
species, including those resistant to carbapenem. Considering the importance of this drug in the current panorama of multidrug-resistant bacteria, we performed a systematic review about ceftazidime–avibactam with emphasis on clinical and pharmacological published data.
Methods
A systematic search of the medical literature was performed. The databases searched included MEDLINE, EMBASE and Web of Science (until September 2017). The search terms used were ‘avibactam’, ‘NXL104’ and ‘AVE1330A’. Bibliographies from those studies were also reviewed. Ceftazidime was not included as a search term, once relevant studies about avibactam in association with other drugs could be excluded. Only articles in English were selected. No statistical analysis or quality validation was included in this review.
Results
A total of 151 manuscripts were included. Ceftazidime–avibactam has limited action against anaerobic bacteria. Avibactam is a potent inhibitor of class A, class C, and some class D enzymes, which includes KPC-2. The best pharmacodynamic profile of ceftazidime–avibactam is ƒT > MIC, validated in an animal model of soft tissue infection. Three clinical trials showed the efficacy of ceftazidime–avibactam in patients with intra-abdominal and urinary infections. Ceftazidime–avibactam has been evaluated versus meropenem/doripenem in hospitalized adults with nosocomial pneumonia, neutropenic patients and pediatric patients.
Conclusion
Ceftazidime–avibactam has a favorable pharmacokinetic profile for severe infections and highly active against carbapenemases of KPC-2 type. |
| doi_str_mv | 10.1007/s15010-017-1096-y |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1961638455</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2018963639</sourcerecordid><originalsourceid>FETCH-LOGICAL-c438t-f4965f8b93ef07ca6f333cf69337ac184b4a5d52063920d2878b114d423af45e3</originalsourceid><addsrcrecordid>eNp1kM9O3DAQh60KVLa0D9ALisSFS8pM7DgxN7SCthISPZQr1sSxwSh_Fjuh2p76Drxhn6TeLhQJqacZab75zehj7CPCJwSojiOWgJADVjmCkvn6DVug4CoHVfEdtgAOkNdYyD32LsY7ACiVqN6yvUIhQiIX7PrbLYWezNiNN95Ql1FcWTPFjIY2-9uGuc9Gl5GZ_DhsOmPdRD9963v7-9cjPfgmzag_ySiL6zjZniZvsmAfvP3xnu066qL98FT32dX52ffll_zi8vPX5elFbgSvp9wJJUtXN4pbB5Uh6TjnxknFeUUGa9EIKtuyAMlVAW1RV3WDKFpRcHKitHyfHW1zV2G8n22cdO-jsV1Hgx3nqFFJlLwWZZnQw1fo3TiHIX2nC8BaSZ6OJAq3lAljjME6vQq-p7DWCHojX2_l6yRfb-Trddo5eEqem962_zaebSeg2AIxjYYbG15O_z_1D8GjkGI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2018963639</pqid></control><display><type>article</type><title>Pharmacological aspects and spectrum of action of ceftazidime–avibactam: a systematic review</title><source>Springer Link</source><creator>Tuon, Felipe Francisco ; Rocha, Jaime L. ; Formigoni-Pinto, Marcelo R.</creator><creatorcontrib>Tuon, Felipe Francisco ; Rocha, Jaime L. ; Formigoni-Pinto, Marcelo R.</creatorcontrib><description>Purpose
Ceftazidime–avibactam is an antimicrobial association active against several
Enterobacteriaceae
species, including those resistant to carbapenem. Considering the importance of this drug in the current panorama of multidrug-resistant bacteria, we performed a systematic review about ceftazidime–avibactam with emphasis on clinical and pharmacological published data.
Methods
A systematic search of the medical literature was performed. The databases searched included MEDLINE, EMBASE and Web of Science (until September 2017). The search terms used were ‘avibactam’, ‘NXL104’ and ‘AVE1330A’. Bibliographies from those studies were also reviewed. Ceftazidime was not included as a search term, once relevant studies about avibactam in association with other drugs could be excluded. Only articles in English were selected. No statistical analysis or quality validation was included in this review.
Results
A total of 151 manuscripts were included. Ceftazidime–avibactam has limited action against anaerobic bacteria. Avibactam is a potent inhibitor of class A, class C, and some class D enzymes, which includes KPC-2. The best pharmacodynamic profile of ceftazidime–avibactam is ƒT > MIC, validated in an animal model of soft tissue infection. Three clinical trials showed the efficacy of ceftazidime–avibactam in patients with intra-abdominal and urinary infections. Ceftazidime–avibactam has been evaluated versus meropenem/doripenem in hospitalized adults with nosocomial pneumonia, neutropenic patients and pediatric patients.
Conclusion
Ceftazidime–avibactam has a favorable pharmacokinetic profile for severe infections and highly active against carbapenemases of KPC-2 type.</description><identifier>ISSN: 0300-8126</identifier><identifier>EISSN: 1439-0973</identifier><identifier>DOI: 10.1007/s15010-017-1096-y</identifier><identifier>PMID: 29110143</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adults ; Anaerobic bacteria ; Animal models ; Antibiotics ; Antimicrobial agents ; Bacteria ; Ceftazidime ; Clinical trials ; Drug resistance ; Evidence-based medicine ; Family Medicine ; General Practice ; Hospitals ; Infectious Diseases ; Internal Medicine ; Medical research ; Medicine ; Medicine & Public Health ; Meropenem ; Minimum inhibitory concentration ; Multidrug resistance ; Neutropenia ; Nosocomial infection ; Patients ; Pediatrics ; Pharmacodynamics ; Pharmacokinetics ; Pharmacology ; Review ; Searching ; Statistical analysis ; Systematic review</subject><ispartof>Infection, 2018-04, Vol.46 (2), p.165-181</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2017</rights><rights>Infection is a copyright of Springer, (2017). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c438t-f4965f8b93ef07ca6f333cf69337ac184b4a5d52063920d2878b114d423af45e3</citedby><cites>FETCH-LOGICAL-c438t-f4965f8b93ef07ca6f333cf69337ac184b4a5d52063920d2878b114d423af45e3</cites><orcidid>0000-0003-3471-1786</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29110143$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tuon, Felipe Francisco</creatorcontrib><creatorcontrib>Rocha, Jaime L.</creatorcontrib><creatorcontrib>Formigoni-Pinto, Marcelo R.</creatorcontrib><title>Pharmacological aspects and spectrum of action of ceftazidime–avibactam: a systematic review</title><title>Infection</title><addtitle>Infection</addtitle><addtitle>Infection</addtitle><description>Purpose
Ceftazidime–avibactam is an antimicrobial association active against several
Enterobacteriaceae
species, including those resistant to carbapenem. Considering the importance of this drug in the current panorama of multidrug-resistant bacteria, we performed a systematic review about ceftazidime–avibactam with emphasis on clinical and pharmacological published data.
Methods
A systematic search of the medical literature was performed. The databases searched included MEDLINE, EMBASE and Web of Science (until September 2017). The search terms used were ‘avibactam’, ‘NXL104’ and ‘AVE1330A’. Bibliographies from those studies were also reviewed. Ceftazidime was not included as a search term, once relevant studies about avibactam in association with other drugs could be excluded. Only articles in English were selected. No statistical analysis or quality validation was included in this review.
Results
A total of 151 manuscripts were included. Ceftazidime–avibactam has limited action against anaerobic bacteria. Avibactam is a potent inhibitor of class A, class C, and some class D enzymes, which includes KPC-2. The best pharmacodynamic profile of ceftazidime–avibactam is ƒT > MIC, validated in an animal model of soft tissue infection. Three clinical trials showed the efficacy of ceftazidime–avibactam in patients with intra-abdominal and urinary infections. Ceftazidime–avibactam has been evaluated versus meropenem/doripenem in hospitalized adults with nosocomial pneumonia, neutropenic patients and pediatric patients.
Conclusion
Ceftazidime–avibactam has a favorable pharmacokinetic profile for severe infections and highly active against carbapenemases of KPC-2 type.</description><subject>Adults</subject><subject>Anaerobic bacteria</subject><subject>Animal models</subject><subject>Antibiotics</subject><subject>Antimicrobial agents</subject><subject>Bacteria</subject><subject>Ceftazidime</subject><subject>Clinical trials</subject><subject>Drug resistance</subject><subject>Evidence-based medicine</subject><subject>Family Medicine</subject><subject>General Practice</subject><subject>Hospitals</subject><subject>Infectious Diseases</subject><subject>Internal Medicine</subject><subject>Medical research</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Meropenem</subject><subject>Minimum inhibitory concentration</subject><subject>Multidrug resistance</subject><subject>Neutropenia</subject><subject>Nosocomial infection</subject><subject>Patients</subject><subject>Pediatrics</subject><subject>Pharmacodynamics</subject><subject>Pharmacokinetics</subject><subject>Pharmacology</subject><subject>Review</subject><subject>Searching</subject><subject>Statistical analysis</subject><subject>Systematic review</subject><issn>0300-8126</issn><issn>1439-0973</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp1kM9O3DAQh60KVLa0D9ALisSFS8pM7DgxN7SCthISPZQr1sSxwSh_Fjuh2p76Drxhn6TeLhQJqacZab75zehj7CPCJwSojiOWgJADVjmCkvn6DVug4CoHVfEdtgAOkNdYyD32LsY7ACiVqN6yvUIhQiIX7PrbLYWezNiNN95Ql1FcWTPFjIY2-9uGuc9Gl5GZ_DhsOmPdRD9963v7-9cjPfgmzag_ySiL6zjZniZvsmAfvP3xnu066qL98FT32dX52ffll_zi8vPX5elFbgSvp9wJJUtXN4pbB5Uh6TjnxknFeUUGa9EIKtuyAMlVAW1RV3WDKFpRcHKitHyfHW1zV2G8n22cdO-jsV1Hgx3nqFFJlLwWZZnQw1fo3TiHIX2nC8BaSZ6OJAq3lAljjME6vQq-p7DWCHojX2_l6yRfb-Trddo5eEqem962_zaebSeg2AIxjYYbG15O_z_1D8GjkGI</recordid><startdate>20180401</startdate><enddate>20180401</enddate><creator>Tuon, Felipe Francisco</creator><creator>Rocha, Jaime L.</creator><creator>Formigoni-Pinto, Marcelo R.</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3471-1786</orcidid></search><sort><creationdate>20180401</creationdate><title>Pharmacological aspects and spectrum of action of ceftazidime–avibactam: a systematic review</title><author>Tuon, Felipe Francisco ; Rocha, Jaime L. ; Formigoni-Pinto, Marcelo R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c438t-f4965f8b93ef07ca6f333cf69337ac184b4a5d52063920d2878b114d423af45e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adults</topic><topic>Anaerobic bacteria</topic><topic>Animal models</topic><topic>Antibiotics</topic><topic>Antimicrobial agents</topic><topic>Bacteria</topic><topic>Ceftazidime</topic><topic>Clinical trials</topic><topic>Drug resistance</topic><topic>Evidence-based medicine</topic><topic>Family Medicine</topic><topic>General Practice</topic><topic>Hospitals</topic><topic>Infectious Diseases</topic><topic>Internal Medicine</topic><topic>Medical research</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Meropenem</topic><topic>Minimum inhibitory concentration</topic><topic>Multidrug resistance</topic><topic>Neutropenia</topic><topic>Nosocomial infection</topic><topic>Patients</topic><topic>Pediatrics</topic><topic>Pharmacodynamics</topic><topic>Pharmacokinetics</topic><topic>Pharmacology</topic><topic>Review</topic><topic>Searching</topic><topic>Statistical analysis</topic><topic>Systematic review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tuon, Felipe Francisco</creatorcontrib><creatorcontrib>Rocha, Jaime L.</creatorcontrib><creatorcontrib>Formigoni-Pinto, Marcelo R.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Infection</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tuon, Felipe Francisco</au><au>Rocha, Jaime L.</au><au>Formigoni-Pinto, Marcelo R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacological aspects and spectrum of action of ceftazidime–avibactam: a systematic review</atitle><jtitle>Infection</jtitle><stitle>Infection</stitle><addtitle>Infection</addtitle><date>2018-04-01</date><risdate>2018</risdate><volume>46</volume><issue>2</issue><spage>165</spage><epage>181</epage><pages>165-181</pages><issn>0300-8126</issn><eissn>1439-0973</eissn><abstract>Purpose
Ceftazidime–avibactam is an antimicrobial association active against several
Enterobacteriaceae
species, including those resistant to carbapenem. Considering the importance of this drug in the current panorama of multidrug-resistant bacteria, we performed a systematic review about ceftazidime–avibactam with emphasis on clinical and pharmacological published data.
Methods
A systematic search of the medical literature was performed. The databases searched included MEDLINE, EMBASE and Web of Science (until September 2017). The search terms used were ‘avibactam’, ‘NXL104’ and ‘AVE1330A’. Bibliographies from those studies were also reviewed. Ceftazidime was not included as a search term, once relevant studies about avibactam in association with other drugs could be excluded. Only articles in English were selected. No statistical analysis or quality validation was included in this review.
Results
A total of 151 manuscripts were included. Ceftazidime–avibactam has limited action against anaerobic bacteria. Avibactam is a potent inhibitor of class A, class C, and some class D enzymes, which includes KPC-2. The best pharmacodynamic profile of ceftazidime–avibactam is ƒT > MIC, validated in an animal model of soft tissue infection. Three clinical trials showed the efficacy of ceftazidime–avibactam in patients with intra-abdominal and urinary infections. Ceftazidime–avibactam has been evaluated versus meropenem/doripenem in hospitalized adults with nosocomial pneumonia, neutropenic patients and pediatric patients.
Conclusion
Ceftazidime–avibactam has a favorable pharmacokinetic profile for severe infections and highly active against carbapenemases of KPC-2 type.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>29110143</pmid><doi>10.1007/s15010-017-1096-y</doi><tpages>17</tpages><orcidid>https://orcid.org/0000-0003-3471-1786</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0300-8126 |
| ispartof | Infection, 2018-04, Vol.46 (2), p.165-181 |
| issn | 0300-8126 1439-0973 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1961638455 |
| source | Springer Link |
| subjects | Adults Anaerobic bacteria Animal models Antibiotics Antimicrobial agents Bacteria Ceftazidime Clinical trials Drug resistance Evidence-based medicine Family Medicine General Practice Hospitals Infectious Diseases Internal Medicine Medical research Medicine Medicine & Public Health Meropenem Minimum inhibitory concentration Multidrug resistance Neutropenia Nosocomial infection Patients Pediatrics Pharmacodynamics Pharmacokinetics Pharmacology Review Searching Statistical analysis Systematic review |
| title | Pharmacological aspects and spectrum of action of ceftazidime–avibactam: a systematic review |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T09%3A45%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacological%20aspects%20and%20spectrum%20of%20action%20of%20ceftazidime%E2%80%93avibactam:%20a%20systematic%20review&rft.jtitle=Infection&rft.au=Tuon,%20Felipe%20Francisco&rft.date=2018-04-01&rft.volume=46&rft.issue=2&rft.spage=165&rft.epage=181&rft.pages=165-181&rft.issn=0300-8126&rft.eissn=1439-0973&rft_id=info:doi/10.1007/s15010-017-1096-y&rft_dat=%3Cproquest_cross%3E2018963639%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c438t-f4965f8b93ef07ca6f333cf69337ac184b4a5d52063920d2878b114d423af45e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2018963639&rft_id=info:pmid/29110143&rfr_iscdi=true |